This study is testing a medicine called pemigatinib for adults with pancreatic cancer that has spread. Pancreatic cancer is when cells in the pancreas grow uncontrollably. Researchers want to see if pemigatinib can stop abnormal genes, called FGFR genes, that help cancer grow.

Patients take pemigatinib by mouth for 14 days in a 21-day cycle. They will have regular check-ups, including blood tests and scans like MRI or CT scans. The study checks if the cancer shrinks and monitors for any side effects.

• The study lasts as long as the medicine works without bad side effects.
• Patients visit the clinic regularly for scans and tests.
• Participants must be adults with certain types of pancreatic cancer gene changes.

Before joining, patients should talk with their doctors about risks, like not knowing all possible side effects, and benefits, like potential cancer control. The study is for those who have tried other treatments that didn’t work or couldn’t be tolerated. Participants must be able to take oral medication and agree to regular follow-ups.